Arvinas Inc - Asset Resilience Ratio
Arvinas Inc (ARVN) has an Asset Resilience Ratio of 75.57% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ARVN liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Arvinas Inc's Asset Resilience Ratio has changed over time. See net assets of Arvinas Inc for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Arvinas Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Arvinas Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $542.50 Million | 75.57% |
| Total Liquid Assets | $542.50 Million | 75.57% |
Asset Resilience Insights
- Very High Liquidity: Arvinas Inc maintains exceptional liquid asset reserves at 75.57% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Arvinas Inc Industry Peers by Asset Resilience Ratio
Compare Arvinas Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Arvinas Inc (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Arvinas Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 75.57% | $542.50 Million | $717.90 Million | -10.46pp |
| 2024-12-31 | 86.03% | $938.90 Million | $1.09 Billion | +13.26pp |
| 2023-12-31 | 72.77% | $949.30 Million | $1.30 Billion | -15.82pp |
| 2022-12-31 | 88.59% | $1.12 Billion | $1.27 Billion | +0.43pp |
| 2021-12-31 | 88.16% | $1.39 Billion | $1.58 Billion | +74.19pp |
| 2020-12-31 | 13.97% | $100.20 Million | $717.40 Million | -76.09pp |
| 2019-12-31 | 90.06% | $271.66 Million | $301.64 Million | -2.59pp |
| 2018-12-31 | 92.65% | $184.64 Million | $199.28 Million | +80.30pp |
| 2017-12-31 | 12.35% | $8.26 Million | $66.85 Million | -67.96pp |
| 2016-12-31 | 80.31% | $30.47 Million | $37.94 Million | -- |
About Arvinas Inc
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing… Read more